THERAPY DOSSIER · th-c3464c258dad

Human plasma-based fibrin matrix used as the culture support for epidermal substitutes

Biologic · No ChEMBL mechanism record. Match is to the fibrin biomaterial itself, not to the cultured epidermal-substitute construct.

Not approved Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL mechanism record. Match is to the fibrin biomaterial itself, not to the cultured epidermal-substitute construct.
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL2108390 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Fibrin; Human fibrin; Factor 1a
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31067012 ↗2019Reported benefit

Influence of fibrin matrices and their released factors on epidermal substitute phenotype and engraftment.

MouseWoundNOD-SCIDSurgical grafting of the cultured epidermal substitute onto the wound bed

Model: Acute full-thickness wound in NOD-SCID mice grafted with cultured epidermal substitutes, as a model for full-thickness burn cover

Human plasma-based fibrin matrix improved keratinocyte migration, proliferation and epidermal substitute organisation compared with fibrin from purified fibrinogen. Both fibrin matrices increased dermal-epidermal junction protein deposition and reduced its degradation, and reduced keratinocyte diff…

Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.

Loading the evidence…